Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Combo Product Dispute Resolution, Primary Mode Of Action Detailed By OCP

This article was originally published in The Gray Sheet

Executive Summary

Combination products without regulatory precedent will be assigned to the FDA center with the most expertise in evaluating the products' primary safety and efficacy concerns, according to a proposed rule published in the May 7 Federal Register

Related Content

Primary-Mode-Of-Action Rule For Combo Products Is Similar To Earlier Draft
Combo Product Coalition Drafting Proposal On Regulatory Selection Criteria
Final Combo Product Dispute Resolution Guidelines Largely Unchanged
Combo Product Office To Tackle Intercenter Agreements, “Chemical Action”
Combo Product Guidances On The March; Primary Mode Of Action Clarified
Combo product QSR
Combo Products Typically Would Require Only One User Fee Payment – FDA
Regulatory News In Brief
Combo Product Industry Coalition Proposal Elevates Post-Approval Issues
Medtronic Gets To Heart Of Cell Therapy Through Genzyme Collaboration



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts